New therapeutic drugs in the management of chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 8, Issue 2, 2002, Pages 106-111

  Rennard, Stephen I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DETERIORATION; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; MORTALITY; PUBLICATION; REVIEW; SIDE EFFECT; STEROID THERAPY; TACHYPHYLAXIS;

EID: 0036168805     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200203000-00005     Document Type: Review

References (54)

1. Global morality, disability and the contribution of risk factors: Global burden of disease study
2. Alternative projection of mortality by cause 1990-2020: Global burden of disease study
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary
4. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1
5. Management of chronic obstructive pulmonary disease: Are we going anywhere?
6. Potential novel therapies for chronic obstructive pulmonary disease
7. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma
8. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)
9. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
10. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
11. The transition dyspnea index (TDI) in assessing improvements in breathlessness following tiotropium (TIO)
12. The impact of COPD exacerbations (EXAC) on health related quality of life (HRQL) is attenuated by tiotropium (TIO)
13. Long-acting beta2-agonists for chronic obstructive pulmonary disease
14. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD
15. Efficacy of salmeterol xinafoate in the treatment of COPD
16. Use of a long-acting inhaled beta(2)-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease
17. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD
18. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease
19. The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD
20. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action
21. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD
22. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: A 3-week, randomized, double-blind, within-patient, multicenter study
23. Formoterol (Foradil®) improves lung function and quality of life (QOL) parameters in patients with reversible or poorly reversible COPD
24. Inhaled formoterol (Foradil®) improves lung function in patients with both reversible and poorly reversible COPD
25. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease: Comparison with albuterol and ipratropium
26. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
27. Bronchodilator responses to anticholinergic and beta-adrenergic agents in acute and stable COPD
28. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone
29. Routine nebulized ipratropium and albuterol together are better than either alone in COPD
30. Anticholinergic bronchodilators
31. Additive effects of salmeterol and fluticasone or theophylline in COPD
32. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD
33. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium
34. Salmeterol plus theophylline combination therapy in the treatment of COPD
35. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease
36. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids
37. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease
38. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
39. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
40. Improvements in airflow and dyspnea in COPD patients following BID treatment with fluticasone propionate (FP) 250MCG and 500MCG for 24 weeks via the Diskus® inhaler
41. Improvements in airflow and dyspnea in COPD patients following 24 weeks treatment with salmeterol 50Mug and fluticasone propionate 250Mug alone or in combination via the diskus
42. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
43. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
44. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease
45. Health status deterioration in patients with chronic obstructive pulmonary disease
46. Fluticasone propionate/salmeterol combination improves quality of life in patients with COPD
47. Improvements in FEV1 and symptoms in COPD patients following 24 weeks of twice daily treatment with salmeterol 50/fluticasone propionate 50 combination
48. Phosphodiesterase isozymes: Molecular targets for novel anti-asthma agents
49. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
50. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo
51. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study
52. Cilomilast (Ariflo®), a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: Results of a 6-month trial
53. Cilomilast (Ariflo®), a potent selective inhibitor of phosphodiesterase 4, improves lung function in COPD patients: Results of a 6-month trial
54. Cilomilast (Ariflo®) improves health status in patients with COPD: Results of a 6-month trial